Risk of COVID-19 in dermatologic patients receiving long-term immunomodulatory therapy

J Am Acad Dermatol. 2020 Oct;83(4):1215-1218. doi: 10.1016/j.jaad.2020.06.999. Epub 2020 Jul 2.

¹ Harvard Combined Dermatology Residency Program, Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts.
² Clinical Laboratory for Epidemiology and Applied Research in Skin (CLEARS), Department of Dermatology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
³ Clinical Laboratory for Epidemiology and Applied Research in Skin (CLEARS), Department of Dermatology, Beth Israel Deaconess Medical Center, Boston, Massachusetts; University of Massachusetts Medical School, Worcester, Massachusetts.
⁴ Department of Pharmacy, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
⁵ Clinical Laboratory for Epidemiology and Applied Research in Skin (CLEARS), Department of Dermatology, Beth Israel Deaconess Medical Center, Boston, Massachusetts; Northeastern University, Boston, Massachusetts.
⁶ Clinical Laboratory for Epidemiology and Applied Research in Skin (CLEARS), Department of Dermatology, Beth Israel Deaconess Medical Center, Boston, Massachusetts; Department of Dermatology, Harvard Medical School, Boston, Massachusetts.
⁷ Clinical Laboratory for Epidemiology and Applied Research in Skin (CLEARS), Department of Dermatology, Beth Israel Deaconess Medical Center, Boston, Massachusetts; Department of Dermatology, Harvard Medical School, Boston, Massachusetts. Electronic address: clears@bidmc.harvard.edu.

No abstract available

MeSH terms